These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 30352843)

  • 21. Brief report on IQOS point-of-sale marketing, promotion and pricing in IQOS retail partner stores in Atlanta, Georgia, USA.
    Henderson KC; Van Do V; Wang Y; Duan Z; Popova L; Spears CA; Weaver SR; Ashley DL; Barker DC; Huang J
    Tob Control; 2023 Aug; 32(e2):e260-e264. PubMed ID: 35918133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolving IQOS packaging designs change perceptions of product appeal, uniqueness, quality and safety: a randomised experiment, 2018, USA.
    Lee JGL; Blanchflower TM; O'Brien KF; Averett PE; Cofie LE; Gregory KR
    Tob Control; 2019 Aug; 28(e1):e52-e55. PubMed ID: 31164489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IQOS marketing strategies in the USA before and after US FDA modified risk tobacco product authorisation.
    Berg CJ; Romm KF; Bar-Zeev Y; Abroms LC; Klinkhammer K; Wysota CN; Khayat A; Broniatowski DA; Levine H
    Tob Control; 2023 Jul; 32(4):418-427. PubMed ID: 34667105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IQOS Marketing in the US: The Need to Study the Impact of FDA Modified Exposure Authorization, Marketing Distribution Channels, and Potential Targeting of Consumers.
    Berg CJ; Abroms LC; Levine H; Romm KF; Khayat A; Wysota CN; Duan Z; Bar-Zeev Y
    Int J Environ Res Public Health; 2021 Oct; 18(19):. PubMed ID: 34639851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IQOS marketing strategies at point-of-sales: a cross-sectional survey with retailers.
    Bar-Zeev Y; Berg CJ; Khayat A; Romm KF; Wysota CN; Abroms LC; Elbaz D; Levine H
    Tob Control; 2023 Aug; 32(e2):e198-e204. PubMed ID: 35140170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unboxed: US Young Adult Tobacco Users' Responses to a New Heated Tobacco Product.
    Kim M; Watkins SL; Koester KA; Mock J; Kim HC; Olson S; Harvanko AM; Ling PM
    Int J Environ Res Public Health; 2020 Nov; 17(21):. PubMed ID: 33153143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of FDA endorsement and modified risk versus exposure messaging in IQOS ads: a randomised factorial experiment among US and Israeli adults.
    Berg CJ; Duan Z; Wang Y; Thrasher JF; Bar-Zeev Y; Abroms LC; Romm KF; Khayat A; Levine H
    Tob Control; 2024 Mar; 33(e1):e69-e77. PubMed ID: 36428095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of modified risk tobacco product claims on beliefs of US adults and adolescents.
    El-Toukhy S; Baig SA; Jeong M; Byron MJ; Ribisl KM; Brewer NT
    Tob Control; 2018 Nov; 27(Suppl 1):s62-s69. PubMed ID: 30158212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Modified Risk Tobacco Product Claims on Consumer Responses.
    Seidenberg AB; Boynton MH; Brewer NT; Lazard AJ; Sheeran P; Ribisl KM
    Nicotine Tob Res; 2024 Mar; 26(4):435-443. PubMed ID: 37791605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Industry marketing of tobacco products on social media: case study of Philip Morris International's IQOS.
    Abroms LC; Wysota CN; Tosakoon S; Khayat A; Duan Z; Bar-Zeev Y; Berg CJ; Levine H
    Tob Control; 2024 Jun; 33(4):518-524. PubMed ID: 36927516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exposure to IQOS ads and reduced exposure claims, and association with perceived risk from COVID-19 on IQOS purchase and use intentions: results from a web-based survey.
    Sharma A; Fix B; Hyland A; Bansal-Travers M; Quisenberry A; O'Connor R
    Front Public Health; 2023; 11():1307484. PubMed ID: 38269390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Creating a market for IQOS: analysis of Philip Morris' strategy to introduce heated tobacco products to the Australian consumer market.
    Watts C; Burton S; Freeman B
    Tob Control; 2022 May; 31(3):458-463. PubMed ID: 33191270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of IQOS health warnings and modified risk claims among young adult cigarette smokers and non-smokers.
    Mays D; Johnson AC; Glasser A; Mercincavage M; Strasser AA
    Tob Control; 2023 Jul; 32(4):505-508. PubMed ID: 34716283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IQOS and cigarette advertising across regulatory periods and population groups in Israel: a longitudinal analysis.
    Khayat A; Levine H; Berg CJ; Shauly-Aharonov M; Manor O; Abroms L; Romm KF; Wysota CN; Bar-Zeev Y
    Tob Control; 2024 Mar; 33(e1):e3-e10. PubMed ID: 36368887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Awareness and interest in IQOS heated tobacco products among youth in Canada, England and the USA.
    Czoli CD; White CM; Reid JL; OConnor RJ; Hammond D
    Tob Control; 2020 Jan; 29(1):89-95. PubMed ID: 30696783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Social Media Discussions on the FDA's Modified Risk Tobacco Product Authorization of IQOS.
    Jun J; Zhang N; Zain A; Mohammadi E
    Subst Use Misuse; 2022; 57(3):472-480. PubMed ID: 34986075
    [No Abstract]   [Full Text] [Related]  

  • 37. United States Food and Drug Administration's authorization of reduced exposure claims for IQOS
    Eckford R; Severini G; Sebrié EM; Muggli ME; Beem A; Rosen D; Crosbie E
    Rev Panam Salud Publica; 2022; 46():e155. PubMed ID: 36245905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of IQOS introduction on Philip Morris International cigarette sales in Spain: a Logarithmic Mean Divisa Index decomposition approach.
    Golpe AA; Martín-Álvarez JM; Galiano A; Asensio E
    Gac Sanit; 2022; 36(4):293-300. PubMed ID: 35219532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of a hypothetical modified risk tobacco product claim on heated tobacco product use intention and perceptions in young adults.
    Chen-Sankey JC; Kechter A; Barrington-Trimis J; McConnell R; Krueger EA; Cruz TB; Unger JB; Chaffee BW; Leventhal A
    Tob Control; 2023 Jan; 32(1):42-50. PubMed ID: 34059552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring the association between the proximity to and density around schools of retailers selling IQOS products and youth use of heated tobacco products: evidence from the 2020-2021 COMPASS study.
    Mott H; Leatherdale ST; Cole AG
    Health Promot Chronic Dis Prev Can; 2024 Jan; 44(1):1-8. PubMed ID: 38231088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.